You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP68)1 May 2024MP68-04 ESTIMATING THE IMPACT OF ENHANCED CARE AT MINORITY-SERVING HOSPITALS ON DISPARITIES IN THE TREATMENT OF PROSTATE CANCER Edoardo Beatrici, Marco Paciotti, David-Dan Nguyen, Dejan K. Filipas, Zhiyu Qian, Filippo D'Agnino, Giovanni Lughezzani, Stuart R. Lipsitz, Adam S. Kibel, Alexander P. Cole, and Quoc-Dien Trinh Edoardo BeatriciEdoardo Beatrici , Marco PaciottiMarco Paciotti , David-Dan NguyenDavid-Dan Nguyen , Dejan K. FilipasDejan K. Filipas , Zhiyu QianZhiyu Qian , Filippo D'AgninoFilippo D'Agnino , Giovanni LughezzaniGiovanni Lughezzani , Stuart R. LipsitzStuart R. Lipsitz , Adam S. KibelAdam S. Kibel , Alexander P. ColeAlexander P. Cole , and Quoc-Dien TrinhQuoc-Dien Trinh View All Author Informationhttps://doi.org/10.1097/01.JU.0001008744.60568.e8.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Minority patients often receive care from a limited number of hospitals, potentially contributing to national care disparities. This study examines treatment differences for prostate cancer (PC) between Minority Serving Hospitals (MSHs) and non-MSHs from 2010-2019. Furthermore, we aimed to estimate the potential impact of eradicating facility-level disparities in access to such treatments specifically for all patients seen at MSHs. Given the high proportion of minority populations served in MSHs, addressing these disparities could significantly reduce the national racial/ethnic disparities at the patient level. METHODS: We identified patients eligible for definitive treatment for PC within the National Cancer Database (2010-2019). Institutions with the highest decile of minority patients, specifically Non-Hispanic Black and Hispanic, were deemed MSHs. Using multivariable logistic regression models adjusted for patient and hospital features, we compared definitive treatment odds between MSHs and non-MSHs. An interaction term between the site of care (non-MSH vs. MSH) and race was then integrated to assess the potential modulation of the site of care effect on definitive treatment by race. Based on the adjusted odds, a simulation model estimated how many more patients would receive treatment if MSH care matched non-MSH standards. RESULTS: A total of 634,100 men with PC were identified from 1,321 hospitals. Overall, 60,248 (9.5%) men were treated at MSHs and 573,852 (90.5%) at non-MSHs. MSHs consistently showed lower odds of delivering definitive therapy for PC (aOR 0.69, 95% CI 0.58-0.82; p-value<0.001). No interaction was reported between the site of care and the race on definitive treatment (p-valueint >0.05). If treatment rates for PC at MSHs matched non-MSHs, the national probability of receiving definitive therapy at MSHs would increase by 4.5% (95% CI 4.4 – 4.6). This would translate into 2692 more men with PC receiving definitive treatment in this cohort. CONCLUSIONS: The study highlights a significant disparity in the definitive treatment delivery between MSHs and non-MSHs for PC. Targeted improvements within MSHs could elevate the standard of care for the general population and play a pivotal role in diminishing racial/ethnic disparities in PC outcomes across the US. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1109 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Edoardo Beatrici More articles by this author Marco Paciotti More articles by this author David-Dan Nguyen More articles by this author Dejan K. Filipas More articles by this author Zhiyu Qian More articles by this author Filippo D'Agnino More articles by this author Giovanni Lughezzani More articles by this author Stuart R. Lipsitz More articles by this author Adam S. Kibel More articles by this author Alexander P. Cole More articles by this author Quoc-Dien Trinh More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Beatrici et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: